Arctic Bioscience - Capital/Financing Update 2023

Arctic Bioscience - Credit facility of NOK 30 mill. established

Through the company's primary bank, Arctic Bioscience has established a credit

facility of NOK 30 million to support the nutra business growth potential. The

credit facility has been entered into on ordinary market terms and has a

duration of 1 year with annual renewal.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

Jone R. Slinning

CFO

Mobile: +47 948 75 469

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel investigational drug candidate.

HRO350 is being developed for treatment of patients with mild-to-moderate

psoriasis. This is a large patient group in need of new effective medicines with

beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.

AI assistant